The Role of TAR DNA Binding Protein 43 (TDP-43) as a CandiDate Biomarker of Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
ALS
TDP-43
biomarker
diagnosis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
28
11
2022
revised:
19
01
2023
accepted:
21
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
TAR DNA-binding protein 43 (TDP-43) aggregation in neuronal cells is recognized as a hallmark of amyotrophic lateral sclerosis (ALS). Although the literature strongly supports the pathogenetic role of TDP-43 in ALS pathogenesis, the role of TDP-43 as a biomarker of ALS is controversial. We performed a systematic review and meta-analysis to assess the diagnostic performance of TDP-43 for ALS. Relevant publications were identified by a systematic literature search on PubMed and Web of Science from their inception to 8 April 2022. Seven studies, including 472 individuals, of whom 254 had ALS according to the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, met the inclusion criteria for our meta-analysis. According to the random-effects model, CSF TDP-43 levels are higher in ALS patients compared with control groups. CSF TDP-43 could represent a biomarker of ALS, but further studies are mandatory before drawing conclusions.
Sections du résumé
BACKGROUND
BACKGROUND
TAR DNA-binding protein 43 (TDP-43) aggregation in neuronal cells is recognized as a hallmark of amyotrophic lateral sclerosis (ALS). Although the literature strongly supports the pathogenetic role of TDP-43 in ALS pathogenesis, the role of TDP-43 as a biomarker of ALS is controversial. We performed a systematic review and meta-analysis to assess the diagnostic performance of TDP-43 for ALS.
METHODS
METHODS
Relevant publications were identified by a systematic literature search on PubMed and Web of Science from their inception to 8 April 2022.
RESULTS
RESULTS
Seven studies, including 472 individuals, of whom 254 had ALS according to the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, met the inclusion criteria for our meta-analysis. According to the random-effects model, CSF TDP-43 levels are higher in ALS patients compared with control groups.
CONCLUSIONS
CONCLUSIONS
CSF TDP-43 could represent a biomarker of ALS, but further studies are mandatory before drawing conclusions.
Identifiants
pubmed: 36766521
pii: diagnostics13030416
doi: 10.3390/diagnostics13030416
pmc: PMC9914415
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Front Neurol. 2021 Jun 14;12:663637
pubmed: 34194383
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):153-174
pubmed: 28054827
J Clin Med. 2022 May 31;11(11):
pubmed: 35683523
J Neurol Sci. 1994 Jul;124 Suppl:96-107
pubmed: 7807156
N Engl J Med. 2017 Jul 13;377(2):162-172
pubmed: 28700839
Front Mol Neurosci. 2019 Feb 14;12:25
pubmed: 30837838
Nat Rev Neurol. 2010 Apr;6(4):211-20
pubmed: 20234357
J Neurol Neurosurg Psychiatry. 2020 Nov 11;:
pubmed: 33177049
Int J Mol Sci. 2021 Jun 02;22(11):
pubmed: 34199367
Neurol India. 2014 Jul-Aug;62(4):347-51
pubmed: 25237937
Dement Geriatr Cogn Disord. 2017;44(3-4):144-152
pubmed: 28848086
Metabolites. 2022 Jul 29;12(8):
pubmed: 36005581
J Biol Chem. 2010 Feb 26;285(9):6826-34
pubmed: 20040602
Nat Commun. 2016 Aug 11;7:12408
pubmed: 27510634
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):102-8
pubmed: 21836033
Brain Sci. 2021 Feb 27;11(3):
pubmed: 33673569
Ann Neurol. 2009 Apr;65(4):470-3
pubmed: 19350673
Amyotroph Lateral Scler. 2011 Mar;12(2):140-3
pubmed: 21126161
Int J Mol Sci. 2021 Jul 30;22(15):
pubmed: 34360978
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Int J Neurosci. 2014 May;124(5):344-9
pubmed: 24066851
Muscle Nerve. 2020 Oct;62(4):528-533
pubmed: 32696574
Int J Mol Sci. 2021 Apr 08;22(8):
pubmed: 33917673
Neural Regen Res. 2022 Jul;17(7):1498-1500
pubmed: 34916432
Lab Med. 2021 Mar 15;52(2):188-196
pubmed: 32926148
Lancet. 2017 Nov 4;390(10107):2084-2098
pubmed: 28552366
Eur J Neurol. 2021 Jun;28(6):1868-1875
pubmed: 33638255
PLoS One. 2017 May 16;12(5):e0177181
pubmed: 28510586
Nat Rev Dis Primers. 2017 Oct 20;3:17085
pubmed: 29052611
PLoS Med. 2021 Mar 29;18(3):e1003583
pubmed: 33780438
Acta Neuropathol Commun. 2019 Mar 29;7(1):50
pubmed: 30922385
Neurology. 2013 Apr 23;80(17):1590-7
pubmed: 23553481
Acta Neuropathol. 2009 Jan;117(1):55-62
pubmed: 18989684
Stat Med. 2003 Sep 15;22(17):2693-710
pubmed: 12939780
Ann Clin Transl Neurol. 2019 Dec;6(12):2489-2502
pubmed: 31742901
Int J Mol Sci. 2022 Sep 16;23(18):
pubmed: 36142742
Science. 2006 Oct 6;314(5796):130-3
pubmed: 17023659